Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exebryl-1 for the treatment of Alzheimer′s disease.

Trial Profile

Exebryl-1 for the treatment of Alzheimer′s disease.

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs PTI 80 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors ProteoTech
  • Most Recent Events

    • 13 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top